alexa Kai Kang | Cleveland Clinic Lerner Research Institute

Journal of Immunooncology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Kai Kang

Kai Kang Kai Kang
Cleveland Clinic Lerner Research Institute

Dr. Kang got comprehensive pharmaceutical training in the pharmaceutical universities in China. He Received his Ph.D. degree in the Chinese University of Hong Kong. Now he is a post-doctoral research fellow in the Department of Immunology, Lerner Research Institute, Cleveland Clinic. He has long experience in translational study in tumor field. His current main interest is to study the immune priming effects of low dose hypomethylation agents against cancer in vitro and in vivo.

Research Interest

Drug research and development; Translational study against human disease; Tumor immunotherapy


Global Speakers in the subject

Global Experts in the subject


Epigenetic Therapy, an Appealing Strategy to Improve Cancer Immunotherapy
Kai Kang
Commentary: J Immunooncol
Angioma Serpiginosum
Kai Kang, Xiaohong Zhou, Caixia Li, Jianhua Feng and Yingjun Fan
Case Report: J Clin Exp Dermatol Res 2012, 3:143
DOI: 10.4172/2155-9554.1000143
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version